Topotarget

Share capital and voting rights at July 31, 2014

CORRECTION: Approval of Onxeo’s admission to secondary listing and trading on NASDAQ OMX Copenhagen

Approval of Onxeo’s admission to secondary listing and trading on NASDAQ OMX Copenhagen

Cross-border merger of BioAlliance Pharma and Topotarget legally effective as of July 22, 2014

CEO of Topotarget to resign

FDA approval of Beleodaq™ (belinostat) for Injection

Report pursuant to the Danish Securities Trading Act, Section 28a

New Articles of Association following capital increase

Capital increase as a result of exercise of warrants

BioAlliance Pharma and Topotarget shareholders approve proposed cross-border merger to create Onxeo

Passing on Extraordinary General Meeting

Notice to Convene Extraordinary General Meeting

Definitive Merger Plan between BioAlliance Pharma and Topotarget – Combined Entity to be Named Onxeo

Topotarget announces interim report for the period January 1 – March 31, 2014

Teleconference regarding interim report for the period January 1 – March 31, 2014

HealthCap IV is committed to vote in support of Topotarget’s proposed merger with BioAlliance Pharma

Major shareholder announcement

Passing on Annual General Meeting

Topotarget and BioAlliance Pharma enter into merger agreement to create a leading orphan oncology company

Notice to convene Annual General Meeting 2014

Topotarget announces financial results for the year ended Dec 31, 2013

Topotarget confirms receipt of acceptance-to-file milestone payment

Teleconference regarding annual report 2013

Belinostat abstract for American Association for Cancer Research 2014

FDA grants acceptance to file and Priority Review for Beleodaq™ (belinostat) NDA in PTCL

Topotarget announces interim report for the period January 1 – December 31, 2013

Teleconference regarding interim report for the period January 1 – December 31, 2013

New Drug Application for belinostat in relapsed or refractory PTCL submitted to the FDA in the USA

Allowance of key belinostat patent in Europe

Final results from CLN-14 study in STS